TransTech Pharma, Inc.:製薬企業の治療薬開発パイプライン2014

【英語タイトル】TransTech Pharma, Inc. - Product Pipeline Review - 2014

Global Markets Directが出版した調査資料(GMDHC06302CDB)・商品コード:GMDHC06302CDB
・発行会社(調査会社):Global Markets Direct
Single UserUSD1,500 ⇒換算¥169,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD3,000 ⇒換算¥339,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム

TransTech Pharma, Inc. – Product Pipeline Review – 2014


Global Markets Direct’s, ‘TransTech Pharma, Inc. – Product Pipeline Review – 2014’, provides an overview of the TransTech Pharma, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of TransTech Pharma, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides brief overview of TransTech Pharma, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of TransTech Pharma, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the TransTech Pharma, Inc.’s pipeline products

Reasons to buy

- Evaluate TransTech Pharma, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of TransTech Pharma, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the TransTech Pharma, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of TransTech Pharma, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of TransTech Pharma, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of TransTech Pharma, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues


Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
TransTech Pharma, Inc. Snapshot 5
TransTech Pharma, Inc. Overview 5
Key Information 5
Key Facts 5
TransTech Pharma, Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
TransTech Pharma, Inc. – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
TransTech Pharma, Inc. – Pipeline Products Glance 10
TransTech Pharma, Inc. – Late Stage Pipeline Products 10
Phase III Products/Combination Treatment Modalities 10
TransTech Pharma, Inc. – Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
TransTech Pharma, Inc. – Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
TransTech Pharma, Inc. – Drug Profiles 14
TTP-488 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
TTP-054 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
TTP-399 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
TTP-814 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
TTP-273 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
TTP-607 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
TransTech Pharma, Inc. – Pipeline Analysis 21
TransTech Pharma, Inc. – Pipeline Products by Target 21
TransTech Pharma, Inc. – Pipeline Products by Route of Administration 22
TransTech Pharma, Inc. – Pipeline Products by Molecule Type 23
TransTech Pharma, Inc. – Pipeline Products by Mechanism of Action 24
TransTech Pharma, Inc. – Recent Pipeline Updates 25
TransTech Pharma, Inc. – Dormant Projects 27
TransTech Pharma, Inc. – Locations And Subsidiaries 28
Head Office 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30



★調査レポート[TransTech Pharma, Inc.:製薬企業の治療薬開発パイプライン2014] (コード:GMDHC06302CDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[TransTech Pharma, Inc.:製薬企業の治療薬開発パイプライン2014]についてメールでお問い合わせ